Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNYBiotechnology
-$6.27 today
- Market cap
- $20.01B
- Beta
- 0.27
- P/E (TTM)
- 63.6
- EPS (TTM)
- $4.34
Volume 2.52M
Average 1.11M
ALNY Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow dips below year-ago levels
Q2 FY2026 free cash flow of $40.64M fell 70.9% year over year, behind the +1141.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 16.5% from the prior quarter.
Context
- Free cash flow amounted to 12.5% of revenue in FY2025, up 10.6 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -70.9% toward the trailing-twelve-month pace of +1141.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 465.38M USD
- Year-over-year change
- +1192.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 465.38M | +1192.7% |
| FY2024 | 2024-12-31 | (42.59M) | -201.5% |
| FY2023 | 2023-12-31 | 41.95M | +106.8% |
| FY2022 | 2022-12-31 | (613.33M) | +14.6% |
| FY2021 | 2021-12-31 | (718.07M) | — |
Free Cash Flow vs competitors
How ALNY compares with its peers on the latest reported figures
- ALNY's LTM Jun 2026 free cash flow of $542.54M is the 2nd largest of the 6 companies compared; the peer median is $283.94M.
- Its year-over-year change of +1141.6% is the highest of 5, against a peer median of -1.7%.
- Free cash flow amounts to 11.3% of revenue for ALNY, versus a peer median of 255.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $616.26M | +103.6% | +2.8% | 64.2% | |
| LTM Jun 2026 | $542.54M | +1141.6% | — | 11.3% | |
| LTM Mar 2026 | $363.63M | -4.6% | -3.3% | 550.2% | |
| LTM Sep 2026 | $283.94M | -281.0% | -4.9% | 63.0% | |
| LTM Mar 2026 | $183.34M | +1.1% | +13.2% | 255.4% | |
| LTM Mar 2026 | $65.67M | — | +2.7% | 7126.6% | |
| Peer median (excluding ALNY) | $283.94M | -1.7% | +2.7% | 255.4% | |
Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (852.82M) | (1.13B) | (440.24M) | (278.16M) | 313.75M |
| Depreciation & Amortization | 47.57M | 44.47M | 54.05M | 56.67M | 55.66M |
| Deferred Income Tax | (55.7M) | 0 | 0 | (106.76M) | (2.2M) |
| Stock-Based Compensation | 165.72M | 230.65M | 221.68M | 272.08M | 348.24M |
| Change in Working Capital | (162.82M) | (35.55M) | 10.76M | (214.08M) | (444.78M) |
| Accounts Receivables | (101.8M) | (45.6M) | (87.94M) | (86.55M) | (359.96M) |
| Inventory | (26.42M) | (34.14M) | 18.37M | 13.59M | 8.47M |
| Accounts Payables | 88.24M | 191.77M | 80.84M | 91.09M | 75.07M |
| Other Working Capital | (122.85M) | (147.59M) | (509K) | (232.22M) | (168.36M) |
| Other Non-Cash Items | 216.37M | 350.32M | 257.91M | 261.94M | 253.42M |
| Operating Cash Flow | (641.69M) | (541.27M) | 104.16M | (8.31M) | 524.08M |
| Capital Expenditures | (76.37M) | (72.06M) | (62.21M) | (34.28M) | (58.7M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.66B) | (1.98B) | (1.82B) | (1.71B) | (1.36B) |
| Sales of Investments | 1.46B | 2.23B | 1.55B | 1.57B | 1.8B |
| Other Investing Activities | (4.36M) | (13.19M) | (4.44M) | 57.76M | 57.63M |
| Investing Cash Flow | (273.3M) | 169.35M | (336.35M) | (116.84M) | 436.33M |
| Debt Repayment | 500M | 254M | 0 | 0 | (546.95M) |
| Common Stock Issued | 246.27M | 259.36M | 147.46M | 302.95M | 250.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 500.85M | (87.61M) | 24.67M | (8.79M) | (8.27M) |
| Financing Cash Flow | 1.25B | 425.75M | 172.13M | 294.16M | (305.19M) |
| Effect of Forex Changes | (9.02M) | (7.43M) | 6.39M | (15.24M) | 34.94M |
| Net Change in Cash | 323.11M | 46.4M | (53.67M) | 153.77M | 690.16M |
| Free Cash Flow | (718.07M) | (613.33M) | 41.95M | (42.59M) | 465.38M |
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Intrinsic Alpha fair value
Locked
Current Price
$149.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.